Emerging biomarkers for immune checkpoint inhibition in lung cancer.
暂无分享,去创建一个
[1] Matthew D. Hellmann,et al. Abstract CT078: Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568 , 2018, Clinical Trials.
[2] M. Socinski,et al. Abstract CT076: IMpower150: Efficacy of atezolizumab (atezo) plus bevacizumab (bev) and chemotherapy (chemo) in 1L metastatic nonsquamous NSCLC (mNSCLC) across key subgroups , 2018, Clinical Trials.
[3] J. Szustakowski,et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden , 2018, The New England journal of medicine.
[4] S. Novello,et al. Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[5] M. Socinski,et al. 134PD Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC (IMpower150) , 2018 .
[6] David C. Smith,et al. Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] M. Socinski,et al. LBA1_PRPrimary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IMPOWER150) , 2017 .
[8] Angela E. Leek,et al. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution , 2017, Cell.
[9] Maximilian Diehn,et al. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers , 2017, Nature Genetics.
[10] Tarek Mekhail,et al. Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[11] Carsten Denkert,et al. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothe , 2017, Advances in anatomic pathology.
[12] J. Taube,et al. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer , 2017, JAMA oncology.
[13] M. Socinski,et al. First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[14] Michael S. Goldberg,et al. DNA Damage and Repair Biomarkers of Immunotherapy Response. , 2017, Cancer discovery.
[15] Jeffrey E. Lee,et al. Association of the diversity and composition of the gut microbiome with responses and survival (PFS) in metastatic melanoma (MM) patients (pts) on anti-PD-1 therapy. , 2017 .
[16] R. Rosell,et al. Interferon-gamma (INFG), an important marker of response to immune checkpoint blockade (ICB) in non-small cell lung cancer (NSCLC) and melanoma patients. , 2017 .
[17] Tae Won Kim,et al. Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC. , 2017 .
[18] L. Zitvogel,et al. Anticancer effects of the microbiome and its products , 2017, Nature Reviews Microbiology.
[19] Robert Damoiseaux,et al. Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression , 2017, Cell reports.
[20] Soumen Roy,et al. Microbiota: a key orchestrator of cancer therapy , 2017, Nature Reviews Cancer.
[21] Nicolai J. Birkbak,et al. Tracking the Evolution of Non‐Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[22] Koichi Araki,et al. Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent , 2016, Science.
[23] C. Zahnow,et al. Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. , 2017, Cancer discovery.
[24] J. Wargo,et al. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.
[25] V. Gebski,et al. Checkpoint Inhibitors in Metastatic EGFR‐Mutated Non–Small Cell Lung Cancer—A Meta‐Analysis , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[26] F. Hirsch,et al. PD‐L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD‐L1 IHC Assay Comparison Project , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[27] T. Graeber,et al. Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. , 2017, Cancer discovery.
[28] Carlos Barrios,et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.
[29] I. Mellman,et al. Elements of cancer immunity and the cancer–immune set point , 2017, Nature.
[30] Alan Sharpe,et al. Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non–Small Cell Lung Cancer , 2017, Clinical Cancer Research.
[31] D. Rimm,et al. Quantitative and Pathologist-Read comparison of the Heterogeneity of Programmed Death-Ligand 1(PD-L1) expression in Non-Small Cell Lung Cancer , 2016, Modern Pathology.
[32] S. Gettinger,et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. , 2017, The Lancet. Oncology.
[33] L. Sequist,et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. , 2016, The Lancet. Oncology.
[34] P. A. Futreal,et al. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set , 2016, BMC Medicine.
[35] Y. Shentu,et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.
[36] M. Tiemann,et al. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas , 2016, Modern Pathology.
[37] S. Gettinger,et al. Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] C. Paweletz,et al. Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes. , 2016, JCI insight.
[39] Liyi Zhang,et al. Upregulation of programmed cell death ligand 1 promotes resistance response in non‐small‐cell lung cancer patients treated with neo‐adjuvant chemotherapy , 2016, Cancer science.
[40] T. Graeber,et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.
[41] Gyan Bhanot,et al. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. , 2016, The Journal of clinical investigation.
[42] Ana C Anderson,et al. Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. , 2016, Immunity.
[43] Keunchil Park,et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial , 2016, The Lancet.
[44] Y. Shentu,et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.
[45] Nicolai J. Birkbak,et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.
[46] K. Steele,et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. , 2016, The Lancet. Oncology.
[47] Shohei Koyama,et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints , 2016, Nature Communications.
[48] C. Marquette,et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[49] L. Zitvogel,et al. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. , 2015, Cancer cell.
[50] S. Murphy,et al. Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer. , 2015, Cancer research.
[51] F. Ginhoux,et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota , 2015, Science.
[52] Jason B. Williams,et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy , 2015, Science.
[53] Jun Chen,et al. Prognostic Role of Tumor-Infiltrating Lymphocytes in Lung Cancer: a Meta-Analysis , 2015, Cellular Physiology and Biochemistry.
[54] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[55] H. Asamura,et al. Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non--Small-Cell Lung Cancer. , 2015, Clinical lung cancer.
[56] G. Coukos,et al. Combining immunotherapy and anticancer agents: the right path to achieve cancer cure? , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[57] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[58] Dirk Schadendorf,et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[59] J. Lunceford,et al. Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.
[60] P. Klenerman,et al. POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer , 2015, Clinical Cancer Research.
[61] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[62] J. Wolchok,et al. Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. , 2015, The New England journal of medicine.
[63] J. Wolchok,et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.
[64] H. Kohrt,et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.
[65] A. Viale,et al. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. , 2014, Blood.
[66] Steven J. M. Jones,et al. Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.
[67] H. Koblish,et al. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment , 2014, Journal of Immunotherapy for Cancer.
[68] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[69] Israel Lowy,et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] G. Freeman,et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. , 2007, Immunity.
[71] Robert D. Schreiber,et al. Interferons, immunity and cancer immunoediting , 2006, Nature Reviews Immunology.
[72] S. Mazmanian,et al. An Immunomodulatory Molecule of Symbiotic Bacteria Directs Maturation of the Host Immune System , 2005, Cell.
[73] Tasuku Honjo,et al. PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells , 2004, Cancer Research.
[74] Yoshimasa Tanaka,et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[75] Haidong Dong,et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.
[76] G. Freeman,et al. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.
[77] G. Zhu,et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion , 1999, Nature Medicine.
[78] M Aguet,et al. The IFN gamma receptor: a paradigm for cytokine receptor signaling. , 1997, Annual review of immunology.